229 related articles for article (PubMed ID: 37323266)
21. The Current Status and Future Prospects for Conversion Therapy in the Treatment of Hepatocellular Carcinoma.
Bai J; Huang M; Song B; Luo W; Ding R
Technol Cancer Res Treat; 2023; 22():15330338231159718. PubMed ID: 36855803
[TBL] [Abstract][Full Text] [Related]
22. Case Report: Hepatic Artery Infusion Chemotherapy After Stage I ALPPS in a Patient With Huge HCC.
Zhuo W; Li A; Yang W; Duan J; Min J; Wei J
Front Surg; 2021; 8():746618. PubMed ID: 34901139
[TBL] [Abstract][Full Text] [Related]
23. Hepatic arterial infusion chemotherapy vs transcatheter arterial embolization for patients with huge unresectable hepatocellular carcinoma.
Tsai WL; Sun WC; Chen WC; Chiang CL; Lin HS; Liang HL; Cheng JS
Medicine (Baltimore); 2020 Aug; 99(32):e21489. PubMed ID: 32769883
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of transcatheter arterial chemoembolization-lenvatinib sequential therapy for patients with unresectable hepatocellular carcinoma: a single-arm clinical study.
Chen R; Li L; Li Y; Song K; Shen C; Ma P; Wang Z
J Gastrointest Oncol; 2022 Jun; 13(3):1367-1375. PubMed ID: 35837188
[TBL] [Abstract][Full Text] [Related]
25. A case of conversion hepatectomy for huge ruptured hepatocellular carcinoma after transarterial embolization and lenvatinib therapy.
Naganuma A; Suzuki Y; Hoshino T; Yasuoka H; Tamura Y; Naruse H; Tanaka H; Hirai K; Sakamoto I; Ogawa T; Hatanaka T; Kakizaki S
Clin J Gastroenterol; 2022 Feb; 15(1):177-184. PubMed ID: 34811701
[TBL] [Abstract][Full Text] [Related]
26. Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors for advanced hepatocellular carcinoma.
Liu BJ; Gao S; Zhu X; Guo JH; Kou FX; Liu SX; Zhang X; Wang XD; Cao G; Chen H; Liu P; Xu HF; Gao QZ; Yang RJ
Immunotherapy; 2021 Dec; 13(17):1395-1405. PubMed ID: 34607482
[TBL] [Abstract][Full Text] [Related]
27. Dual transformation therapy for giant hepatocellular carcinoma: Two case reports and review of literature.
Gao Q; Zhu GZ; Han CY; Ye XP; Huang HS; Mo ST; Peng T
World J Gastrointest Surg; 2023 Sep; 15(9):2089-2097. PubMed ID: 37901744
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of bi-monthly hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma.
Moriya K; Namisaki T; Sato S; Douhara A; Furukawa M; Kawaratani H; Kaji K; Kitade M; Shimozato N; Sawada Y; Seki K; Saikawa S; Takaya H; Akahane T; Mitoro A; Okura Y; Yamao J; Yoshiji H
J Gastrointest Oncol; 2018 Aug; 9(4):741-749. PubMed ID: 30151271
[TBL] [Abstract][Full Text] [Related]
29. Hepatic Arterial Infusion Chemotherapy as a Timing Strategy for Conversion Surgery to Treat Hepatocellular Carcinoma: A Single-Center Real-World Study.
Wang J; Zheng Z; Wu T; Li W; Wang J; Pan Y; Peng W; Hu D; Hou J; Xu L; Zhang Y; Chen M; Zhang R; Zhou Z
J Hepatocell Carcinoma; 2022; 9():999-1010. PubMed ID: 36132426
[TBL] [Abstract][Full Text] [Related]
30. Trans-arterial p53-gene-embolization with gelatin sponge microparticles for hepatocellular carcinoma with BCLC stage B: single-center experience.
Liu Y; Zhang Y; Bautista D; Tang S; Zhou J; Li C; Zhao G
Cell Biochem Biophys; 2015 Jan; 71(1):99-104. PubMed ID: 25323562
[TBL] [Abstract][Full Text] [Related]
31. [Combination Chemotherapy Using Sorafenib and Hepatic Arterial Infusion with a Fine-Powder Formulation of Cisplatin for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis--A Case Report].
Tsukamoto T; Kanazawa A; Shimizu S; Murata A; Sakae M; Kurihara S; Tashima T; Deguchi S; Nakai T; Kawasaki Y; Kioka K
Gan To Kagaku Ryoho; 2015 Nov; 42(12):1878-80. PubMed ID: 26805203
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant hepatic arterial infusion chemotherapy after radical hepatectomy for hepatocellular carcinoma--results of long-term follow-up.
Asahara T; Itamoto T; Katayama K; Ono E; Dohi K; Nakanishi T; Kitamoto M; Azuma K; Ito K
Hepatogastroenterology; 1999; 46(26):1042-8. PubMed ID: 10370664
[TBL] [Abstract][Full Text] [Related]
33. Conversion surgery after preoperative therapy for advanced hepatocellular carcinoma in the era of molecular targeted therapy and immune checkpoint inhibitors.
Arita J; Ichida A; Nagata R; Mihara Y; Kawaguchi Y; Ishizawa T; Akamatsu N; Kaneko J; Hasegawa K
J Hepatobiliary Pancreat Sci; 2022 Jul; 29(7):732-740. PubMed ID: 35306748
[TBL] [Abstract][Full Text] [Related]
34. Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial.
Lai Z; He M; Bu X; Xu Y; Huang Y; Wen D; Li Q; Xu L; Zhang Y; Wei W; Chen M; Kan A; Shi M
Eur J Cancer; 2022 Oct; 174():68-77. PubMed ID: 35981413
[TBL] [Abstract][Full Text] [Related]
35. Surgical Resection of a Recurrent Hepatocellular Carcinoma with Portal Vein Thrombosis: Is It a Good Treatment Option? A Case Report and Systematic Review of the Literature.
Sena G; Paglione D; Gallo G; Goglia M; Osso M; Nardo B
J Clin Med; 2022 Sep; 11(18):. PubMed ID: 36142934
[TBL] [Abstract][Full Text] [Related]
36. Pathological complete response by advanced hepatocellular carcinoma with massive macrovascular invasion to hepatic arterial infusion chemotherapy: a case report.
Sano S; Nakata S; Wada S; Kuroiwa M; Sakai H; Kusama K; Machida T; Nishio A; Ito I; Sodeyama H
World J Surg Oncol; 2019 Dec; 17(1):229. PubMed ID: 31878937
[TBL] [Abstract][Full Text] [Related]
37. Successful totally laparoscopic right trihepatectomy following conversion therapy for hepatocellular carcinoma: A case report.
Zhang JJ; Wang ZX; Niu JX; Zhang M; An N; Li PF; Zheng WH
World J Clin Cases; 2021 Aug; 9(22):6469-6477. PubMed ID: 34435014
[TBL] [Abstract][Full Text] [Related]
38. Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: A tertiary medical center experience.
Luo L; Xiao Y; Zhu G; Huang A; Song S; Wang T; Ge X; Xie J; Deng W; Hu Z; Wen W; Mei H; Wan R; Shan R
Front Oncol; 2022; 12():1004652. PubMed ID: 36237309
[TBL] [Abstract][Full Text] [Related]
39. Conversion Surgery After Atezolizumab Plus Bevacizumab for Primary and Peritoneal Metastasis After Hepatocellular Carcinoma Rupture.
Miyata T; Sugi K; Horino T; Ono A; Tagayasu Y; Nomoto D; Inoue M; Mizumoto T; Kubota T; Yanagida E; Murayama T; Miyanari N; Baba H
Anticancer Res; 2023 Feb; 43(2):943-947. PubMed ID: 36697062
[TBL] [Abstract][Full Text] [Related]
40. Hepatic Arterial Infusion Chemotherapy Is a Feasible Treatment Option for Hepatocellular Carcinoma: A New Update.
Hendi M; Mou Y; Lv J; Zhang B; Cai X
Gastrointest Tumors; 2021 Oct; 8(4):145-152. PubMed ID: 34722467
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
